Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)

Sanofi says it may look at next gen­er­a­tion of weight loss drugs: #JPM24

SAN FRAN­CIS­CO — Sanofi might not be done with the weight loss space af­ter all.

Af­ter its own GLP-1 drug failed a mid-stage tri­al al­most half a decade ago, the French drug­mak­er missed out on what has be­come the biggest new drug cat­e­go­ry of the decade. On Wednes­day at the JP Mor­gan Health­care Con­fer­ence, top ex­ec­u­tives at the com­pa­ny said they could look at po­ten­tial next-gen­er­a­tion prod­ucts in the years to come that could be more tar­get­ed or have bet­ter side ef­fects.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.